PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10218708

Familial exudative vitreoretinopathy mimicking persistent hyperplastic primary vitreous.

A Chang-Godinich·E A Paysse·D K Coats·E R Holz
View original source ↗Export metadata ↓

Abstract

PURPOSE: To report an unusual case of familial exudative vitreoretinopathy in an infant. METHODS: Case report. A 6-day-old girl had unilateral microphthalmia in the right eye, with a retrolental plaque initially diagnosed as persistent hyperplastic primary vitreous. Three months later, peripheral retinal vascular changes and a fibrovascular ridge were noted in the left eye, suggesting familial exudative vitreoretinopathy as the cause in both eyes. RESULTS: The microphthalmic right eye was unsalvageable. The left eye developed an exudative retinal detachment despite photocoagulation of the peripheral avascular retina. Additional cryotherapy resulted in resolution of the detachment and regression of the vascular changes. CONCLUSIONS: With highly asymmetric involvement, neonatal familial exudative vitreoretinopathy can mimic persistent hyperplastic primary vitreous. Fellow eye involvement can progress rapidly.

Explore related subjects

CryotherapyDiagnosis, DifferentialExudates and TransudatesEye Diseases, HereditaryFemaleFundus OculiHumansHyperplasiaInfant, NewbornLaser CoagulationMicrophthalmosRetinal DetachmentRetinal DiseasesUltrasonographyVitreous BodyCase ReportsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Chang-Godinich, E A Paysse, D K Coats, E R Holz. 1999. Familial exudative vitreoretinopathy mimicking persistent hyperplastic primary vitreous.. https://doi.org/10.1016/s0002-9394(99)00003-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Current status of HIFU and cryotherapy in prostate cancer--a review.

OBJECTIVES: To evaluate the current status of high-intensity focused ultrasound (HIFU) and cryosurgery as the primary treatment option in patients with prostate cancer. METHOD: A MedLine search using specified search terms was done on February 28, 2005. This search rendered 150 papers related to HIFU and 566 papers related to cryosurgery. Very few of these papers presented original outcome data and are included in the present review. RESULTS: No controlled trial was available for analysis, and no survival data were presented. No validated biochemical, surrogate end point was available for any of the two therapies. HIFU showed progression-free survival (based on prostate-specific antigen+/-biopsy data) of 63-87% (projected 3- to 5-yr data), but median follow-up in the studies ranged from 12-24 mo. Negative postoperative biopsies was seen in 82-94% of patients. Complications have been reduced by the combination of transurethral resection of the prostate and HIFU. Cryosurgery showed a progression-free survival of 36-92% (projected 1-7 yr data), depending on risk groups and definition of failure. Negative biopsies were seen in 72-87%, but no biopsy data were available for the currently used third-generation cryotherapy machines. Complications seem to be lower with the third-generation machines. CONCLUSIONS: None of the evaluated therapies has enough data available to support their use as an alternative to established therapies (surgery, radiation) for localised prostate cancer. Until further data become available, the use of both treatments should be restricted to patients unfit for established therapies who still have the need for local therapy.

Cryotherapy↗
PubMed2006

Thermal and flow measurements of continuous cryogenic spray cooling.

The performance of single sprays for high heat flux cooling using R-134a was studied. The heat flux and heat transfer coefficient at the surface of a sprayed jet based on measurements of steady-state temperature gradients on a thin copper plate during continuous spraying. Meanwhile, the spray droplets flow characteristics was also quantified through laser doppler velocimetry (LDV) measurements to obtain the local velocity distributions. The effects of mass flow rate and average droplet velocity, and spray exit-to-target distance on the surface heat flux including the corresponding critical heat flux (CHF) were explored through three different nozzle diameters of 0.2, 0.3, and 0.4 mm. Finally, the effective use of the fluid being delivered based on the cooling efficiency and cooling effectiveness was also examined. The relationship between CHF and nozzle performance in terms of cooling efficiency and cooling effectiveness was found. The heat transfer removal rate can reach up to 140 W/cm(2) for the present nozzle size of d (j)=0.2 and 0.3 mm, which may enhance the current cryogen spray cooling (CSC) technique that assists laser therapy of dermatoses.

Cryotherapy↗